1-3 of 3
Oliver Staak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of the Sequential High-Dose Chemotherapy Followed by Autologous Stem Cell Support with and without Rituximab in Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma.

Michal Sieniawski, Jan Oliver Staak, Helena Scheuss, Jan Peter Glossmann, Volker Diehl, Andreas Engert, Andreas Josting
Journal: Blood
Blood (2004) 104 (11): 919.
https://doi.org/10.1182/blood.V104.11.919.919
Published: 2004
Journal Articles

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma

Peter Borchmann, John F. Treml, Hinrich Hansen, Claudia Gottstein, Roland Schnell, Oliver Staak, Hui-fen Zhang, Thomas Davis, Tibor Keler, Volker Diehl, Robert F. Graziano, Andreas Engert
Journal: Blood
Blood (2003) 102 (10): 3737–3742.
https://doi.org/10.1182/blood-2003-02-0515
Published: 2003
Journal Articles

Treatment of relapsed CD20 + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

Clinical Trials & Observations
Ute Rehwald, Holger Schulz, Marcel Reiser, Markus Sieber, Jan Oliver Staak, Franck Morschhauser, Christoph Driessen, Thomas Rüdiger, Konrad Müller-Hermelink, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2003) 101 (2): 420–424.
https://doi.org/10.1182/blood.V101.2.420
Published: 2003